Cash-strapped biotechs find financing alternative

  • An Erratum to this article was published on 01 December 2004

Publicly quoted biotech companies increasingly rely on private investors to raise money

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Author information

Related links

Related links

Related links in Nature Research

IPO floodgates unlikely to open after Ark floatation

IPO plans sour on both sides of the pond

Related external links

Private Raise

Rights and permissions

Reprints and Permissions

About this article

Further reading